// App-Quantinova.ai

S1-05 : A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): Results from NRG Oncology/NSABP B-42

Researchers

Presenter

  • EP Mamounas

Principal Investigators

  • H Bandos

  • BC Lembersky

  • CE Geyer, Jr

  • L Fehrenbacher

  • ML Graham

  • SL Chia

  • AM Brufsky

  • BT Hennessy

  • GS Soori

  • SR Dakil

  • TE Seay

  • JL Wade, III

  • EC McCarron

  • S Paik

  • SM Swain

  • DL Wickerham

Medical Centers

  • MedStar Franklin Square Medical Center, Weinberg Cancer Institute, Baltimore, MD

  • Kaiser Permanente Oncology Clinical Trials Northern California - Vallejo, Vallejo, CA

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Massey Cancer Center, Virginia Commonwealth University, Richmond, VA

  • Allegheny Health Network Cancer Institute, Pittsburgh, PA

  • UF Health Cancer Center at Orlando Health, Orlando, FL

  • Severance Biomedical Sci Inst and Yonsei Univ College of Medicine, Seoul, Korea

  • Missouri Valley Cancer Consortium, Omaha, NE

  • University of Pittsburgh Cancer Institute, Pittsburgh, PA

  • Wichita NCORP/Cancer Center of Kansas, Wichita, KS

  • Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

  • Southeast Cancer Control Consortium, CCOP, Goldsboro, NC

  • University of Pittsburgh, Pittsburgh, PA

  • Georgia NCI Community Oncology Research Program, Atlanta, GA

  • CCOP, Central Illinois, Decatur, IL

  • Cancer Trials Ireland Formerly known as Irish Clinical Oncology Research Group - ICORG, Dublin, Ireland

  • NRG Oncology/NSABP NSABP Legacy Trials Are Now Part of the NRG Oncology Portfolio, Pittsburgh, PA

Locations

  • United States

  • Canada

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

  • Stromal interaction molecule 1

Drug/Treatment

  • Letrozole

  • Tamoxifen

Outcome

  • N/A

Study Design

  • randomized

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved